Ultragenyx Pharmaceutical Inc. Stock price

Equities

RARE

US90400D1081

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2023-09-29 pm EDT Intraday chart for Ultragenyx Pharmaceutical Inc. 5-day change 1st Jan Change
35.65 USD +1.36% -2.14% -23.05%
Sales 2023 * 440 M Sales 2024 * 536 M Capitalization 2 514 M
Net income 2023 * -612 M Net income 2024 * -520 M EV / Sales 2023 *
4,88x
Net cash position 2023 * 365 M Net cash position 2024 * 291 M EV / Sales 2024 *
4,14x
P/E ratio 2023 *
-4,12x
P/E ratio 2024 *
-5,29x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float95.62%
More Fundamentals * Assessed data
Dynamic Chart
Ultragenyx Pharmaceutical Gets Canadian Approval for Severe Hypercholesterolemia Treatment MT
Ultragenyx Says the Cholesterol Evkeeza Gets Canadian Approval DJ
Ultragenyx Pharmaceutical Gets Canadian Approval for Severe Hypercholesterolemia Treatment MT
Ultragenyx Pharmaceutical Inc. Launches Evkeeza (Enacumab for Injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia CI
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 08:50 AM CI
Insider Sell: Ultragenyx Pharmaceutical MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-06-2023 08:50 AM CI
Henrietta Lacks' family sues Ultragenyx over use of HeLa cell line RE
Wedbush Trims Ultragenyx Pharmaceutical's PT to $47 From $49, Keeps Neutral Rating MT
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2023 Earnings Call, Aug 03, 2023 CI
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2023 CI
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q2 Revenue $108.3M MT
Ultragenyx Begins Dosing in Second Cohort in Wilson Disease Trial MT
Ultragenyx Pharmaceutical Inc. Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease CI
More news
1 day+1.36%
1 week-2.14%
Current month-3.10%
1 month-2.52%
3 months-23.58%
6 months-8.75%
Current year-23.05%
More quotes
1 week
34.81
Extreme 34.81
38.41
1 month
34.81
Extreme 34.81
41.99
Current year
34.33
Extreme 34.33
54.98
1 year
33.36
Extreme 33.36
54.98
3 years
33.36
Extreme 33.36
179.65
5 years
31.99
Extreme 31.99
179.65
10 years
31.99
Extreme 31.99
179.65
More quotes
Date Price Change Volume
23-09-29 35.65 +1.36% 453 576
23-09-28 35.17 -4.71% 592,651
23-09-27 36.91 -1.34% 640,979
23-09-26 37.41 +2.02% 874,945
23-09-25 36.67 +0.66% 713,493

Delayed Quote Nasdaq, September 29, 2023 at 04:00 pm EDT

More quotes
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company's four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
35.17USD
Average target price
91.16USD
Spread / Average Target
+159.19%
Consensus
  1. Markets
  2. Equities
  3. Stock Ultragenyx Pharmaceutical Inc. - Nasdaq
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer